197 related articles for article (PubMed ID: 18006840)
1. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.
Rybak JN; Roesli C; Kaspar M; Villa A; Neri D
Cancer Res; 2007 Nov; 67(22):10948-57. PubMed ID: 18006840
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
[TBL] [Abstract][Full Text] [Related]
3. A proteomic approach for the identification of vascular markers of liver metastasis.
Borgia B; Roesli C; Fugmann T; Schliemann C; Cesca M; Neri D; Giavazzi R
Cancer Res; 2010 Jan; 70(1):309-18. PubMed ID: 19996283
[TBL] [Abstract][Full Text] [Related]
4. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
5. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.
Birchler MT; Milisavlijevic D; Pfaltz M; Neri D; Odermatt B; Schmid S; Stoeckli SJ
Laryngoscope; 2003 Jul; 113(7):1231-7. PubMed ID: 12838025
[TBL] [Abstract][Full Text] [Related]
6. Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.
Kischel P; Waltregny D; Castronovo V
Expert Rev Proteomics; 2007 Dec; 4(6):727-39. PubMed ID: 18067412
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
Nilsson F; Kosmehl H; Zardi L; Neri D
Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
[TBL] [Abstract][Full Text] [Related]
8. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
Rybak JN; Ettorre A; Kaissling B; Giavazzi R; Neri D; Elia G
Nat Methods; 2005 Apr; 2(4):291-8. PubMed ID: 15782212
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells.
Roesli C; Borgia B; Schliemann C; Gunthert M; Wunderli-Allenspach H; Giavazzi R; Neri D
Cancer Res; 2009 Jul; 69(13):5406-14. PubMed ID: 19491280
[TBL] [Abstract][Full Text] [Related]
10. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.
Castronovo V; Kischel P; Guillonneau F; de Leval L; Deféchereux T; De Pauw E; Neri D; Waltregny D
Proteomics; 2007 Apr; 7(8):1188-96. PubMed ID: 17372937
[TBL] [Abstract][Full Text] [Related]
11. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature.
Roesli C; Neri D; Rybak JN
Nat Protoc; 2006; 1(1):192-9. PubMed ID: 17406232
[TBL] [Abstract][Full Text] [Related]
12. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.
Paulitschke V; Kunstfeld R; Mohr T; Slany A; Micksche M; Drach J; Zielinski C; Pehamberger H; Gerner C
J Proteome Res; 2009 May; 8(5):2501-10. PubMed ID: 19222175
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeting amino acid auxotrophic Salmonella typhimurium.
Hoffman RM
Amino Acids; 2009 Sep; 37(3):509-21. PubMed ID: 19291366
[TBL] [Abstract][Full Text] [Related]
14. Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R.
Nanda A; Buckhaults P; Seaman S; Agrawal N; Boutin P; Shankara S; Nacht M; Teicher B; Stampfl J; Singh S; Vogelstein B; Kinzler KW; St Croix B
Cancer Res; 2004 Dec; 64(23):8507-11. PubMed ID: 15574754
[TBL] [Abstract][Full Text] [Related]
15. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.
Raynaud CM; Mercier O; Commo F; Dartevelle P; Gomez-Roca C; de Montpreville V; Sabatier L; Soria JC
Lung Cancer; 2009 Aug; 65(2):144-9. PubMed ID: 19091442
[TBL] [Abstract][Full Text] [Related]
16. Relationship of fibronectin and CD44v6 expression with invasive growth and metastasis of liver cancer.
Jha RK; Ma Q; Chen S; Sha H; Ding S
Cancer Invest; 2009 Mar; 27(3):324-8. PubMed ID: 19194823
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.
Brack SS; Silacci M; Birchler M; Neri D
Clin Cancer Res; 2006 May; 12(10):3200-8. PubMed ID: 16707621
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
Silacci M; Brack SS; Späth N; Buck A; Hillinger S; Arni S; Weder W; Zardi L; Neri D
Protein Eng Des Sel; 2006 Oct; 19(10):471-8. PubMed ID: 16928692
[TBL] [Abstract][Full Text] [Related]
19. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
[TBL] [Abstract][Full Text] [Related]
20. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
